Barclays PLC Increases Holdings in Sana Biotechnology, Inc. (NASDAQ:SANA)

Barclays PLC grew its position in Sana Biotechnology, Inc. (NASDAQ:SANA) by 126.6% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 318,910 shares of the company’s stock after buying an additional 178,179 shares during the period. Barclays PLC’s holdings in Sana Biotechnology were worth $1,325,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Sana Biotechnology by 20.6% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 29,858 shares of the company’s stock valued at $163,000 after acquiring an additional 5,090 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Sana Biotechnology by 2.8% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 253,899 shares of the company’s stock valued at $1,056,000 after purchasing an additional 6,823 shares during the period. Arizona State Retirement System boosted its holdings in Sana Biotechnology by 36.7% in the second quarter. Arizona State Retirement System now owns 37,028 shares of the company’s stock worth $202,000 after purchasing an additional 9,940 shares during the last quarter. Stifel Financial Corp purchased a new stake in Sana Biotechnology in the third quarter worth approximately $43,000. Finally, EP Wealth Advisors LLC bought a new stake in Sana Biotechnology in the 3rd quarter worth approximately $45,000. 88.23% of the stock is owned by institutional investors.

Sana Biotechnology Price Performance

Shares of SANA stock opened at $1.61 on Friday. The company has a market cap of $359.46 million, a price-to-earnings ratio of -1.15 and a beta of 1.33. Sana Biotechnology, Inc. has a 1 year low of $1.55 and a 1 year high of $12.00. The firm has a fifty day moving average price of $2.68 and a 200-day moving average price of $4.30.

Sana Biotechnology (NASDAQ:SANA) last released its earnings results on Friday, November 8th. The company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.01. Equities research analysts expect that Sana Biotechnology, Inc. will post -1.16 EPS for the current year.

Wall Street Analysts Forecast Growth

SANA has been the topic of several research analyst reports. HC Wainwright reissued a “buy” rating and set a $8.00 price target on shares of Sana Biotechnology in a report on Wednesday, November 27th. JMP Securities lowered shares of Sana Biotechnology from an “outperform” rating to a “market perform” rating in a research report on Tuesday, November 5th.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.